# Phase 1 to Evaluate the Safety and Pharmacokinetic Durg-drug Interaction of YYC506-T and YYC506-A

> **NCT04874142** · PHASE1 · COMPLETED · sponsor: **Yooyoung Pharmaceutical Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** YYC506-T
- **DRUG:** YYC506-A
- **DRUG:** YYC506-T + YYC506-A
- **DRUG:** YYC506-A + YYC506-T

## Key facts

- **NCT ID:** NCT04874142
- **Lead sponsor:** Yooyoung Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-20
- **Primary completion:** 2020-03-23
- **Final completion:** 2020-03-23
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04874142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04874142, "Phase 1 to Evaluate the Safety and Pharmacokinetic Durg-drug Interaction of YYC506-T and YYC506-A". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04874142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*